Physician profile
Sarah E Hammonds
NPI 1912490020
$4,822.90
in general payments reported to CMS, 2019-2025
26 companies · $1,209 in 2025
The $1,209 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,279 · 2022: $571 · 2023: $648 · 2024: $1,116 · 2025: $1,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,972.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $818.64 | 2021-2024 | Senza |
| Abbott Laboratories | $767.46 | 2021-2025 | Proclaim, Eterna, Ionicrf |
| Globus Medical, INC. | $524.50 | 2025 | Senza, Omnia |
| Boston Scientific Corporation | $451.54 | 2021-2025 | Intracept, Intracept Rf Probe, General - Pain Management |
| Novo Nordisk INC | $336.38 | 2021-2024 | Wegovy |
| Collegium Pharmaceutical, INC. | $310.83 | 2021-2024 | Belbuca |
| Merz Pharmaceuticals, LLC | $208.46 | 2021-2025 | Xeomin |
| Ipsen Biopharmaceuticals, INC | $195.35 | 2021-2025 | Dysport |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.58 | 2021-2025 | Relistor |
| Currax Pharmaceuticals LLC | $133.07 | 2022-2023 | Contrave |
| Lilly USA, LLC | $124.99 | 2022-2024 | Zepbound |
| Valinor Pharma, LLC | $122.29 | 2023-2024 | Movantik |
| Scilex Pharmaceuticals INC. | $97.54 | 2021-2024 | Ztlido |
| Averitas Pharma INC. | $93.67 | 2023-2025 | Qutenza |
| Ibsa Pharma INC. | $87.58 | 2024-2025 | Tirosint, Licart, Flector |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $75.00 | 2022 | |
| Arbor Pharmaceuticals, INC. | $68.11 | 2021 | |
| Abbvie INC. | $52.94 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $39.96 | 2022 | |
| Dynasplint Systems INC. | $39.94 | 2025 | Dynasplint |
| Almatica Pharma LLC | $39.71 | 2021 | |
| Horizon Therapeutics Plc | $35.11 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $31.16 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $14.89 | 2025 | |
| Azurity Pharmaceuticals, INC. | $13.69 | 2024 | Horizant |
| Relievant Medsystems, INC. | $6.51 | 2023 | Intracept |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Hammonds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.